𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A phase I clinical trial of recombinant human tumor necrosis factor

✍ Scribed by Edward T. Creagan; John S. Kovach; Charles G. Moertel; Stephen Frytak; Larry K. Kvols

Publisher
John Wiley and Sons
Year
1988
Tongue
English
Weight
561 KB
Volume
62
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Recombinant human tumor necrosis factor
Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial
✍ John C. Davis Jr.; DΓ©sirΓ©e Van Der Heijde; Jurgen Braun; Maxime Dougados; John C πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 91 KB πŸ‘ 1 views

## Abstract ## Objective To determine the safety and efficacy of etanercept in a multicenter, randomized, placebo‐controlled, double‐blind trial of adults with moderate to severe active ankylosing spondylitis (AS). ## Methods Patients (n = 277) were treated with either etanercept 25 mg (n = 138)

Effect of recombinant human tumor necros
Effect of recombinant human tumor necrosis factor on tumor and spleen in mice
✍ E. Knippel; J. Rychly; H. A. Schulze; B. Ringel; A. Krygier-Stojalowska πŸ“‚ Article πŸ“… 1988 πŸ› John Wiley and Sons 🌐 French βš– 580 KB

The ability of recombinant human tumor necrosis factor (rH-TNF-alpha) to induce regression of sarcoma 180 in vivo was evaluated. The tumor was cured by TNF in the course of 4 weeks. TNF inhibited proliferation of sarcoma 180 cells in vitro, which suggests a direct effect of TNF on tumor cells in viv